Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC8 | Q9BY41 | 4/20 | 0.63 |
| ▸ | DPP8 | Q6V1X1 | 8/20 | 0.62 |
| ▸ | DPP7 | Q9UHL4 | 6/20 | 0.62 |
| ▸ | DPP9 | Q86TI2 | 4/20 | 0.61 |
| ▸ | ACE | P12821 | 2/20 | 0.56 |
| ▸ | NLN | Q9BYT8 | 1/20 | 0.55 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.52 |
| ▸ | DPP4 | P27487 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14812392 | 0.85 | HDAC3 (0.64) | HDAC8DPP8DPP7DPP9ACE | |
| SCHEMBL4952073 | 0.82 | HDAC8 (0.74) | HDAC8DPP8DPP7DPP9ACE | |
| SCHEMBL10422997 | 0.79 | ACE (0.67) | HDAC8DPP8DPP7DPP9ACE | |
| SCHEMBL10422998 | 0.79 | ACE (0.67) | HDAC8DPP8DPP7DPP9ACE | |
| SCHEMBL1358772 | 0.78 | HDAC8 (0.97) | HDAC8DPP8DPP7DPP9ACE | |
| SCHEMBL1358775 | 0.78 | HDAC8 (0.97) | HDAC8DPP8DPP7DPP9ACE | |
| SCHEMBL9032632 | 0.77 | DPP8 (0.82) | HDAC8DPP8DPP7DPP9ACE | |
| SCHEMBL9032640 | 0.77 | DPP8 (0.82) | HDAC8DPP8DPP7DPP9ACE | |
| SCHEMBL14392412 | 0.77 | DPP8 (1.00) | HDAC8DPP8DPP7DPP9NLN | |
| SCHEMBL21746926 | 0.76 | DPP7 (1.00) | HDAC8DPP8DPP7DPP9DPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200291086-A1 | BIOREVERSABLE PROMOIETIES FOR NITROGEN-CONTAINING AND HYDROXYL-CONTAINING DRUGS | Han, Jie (US) | 2020-09-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200291086-A1 | BIOREVERSABLE PROMOIETIES FOR NITROGEN-CONTAINING AND HYDROXYL-CONTAINING DRUGS | NOS2, EGLN2, HPGD | HDAC8 1264/4885DPP8 1691/4885DPP7 1301/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.